End-of-day quote
Korea S.E.
06:00:00 2024-06-19 pm EDT
|
5-day change
|
1st Jan Change
|
1,845
KRW
|
+0.71%
|
|
-3.71%
|
-50.93%
|
Fiscal Period: December |
2022
|
2023
|
---|
Capitalization
1 |
159,514
|
86,747
|
Enterprise Value (EV)
1 |
127,934
|
67,207
|
P/E ratio
|
-13.3
x
|
-6.96
x
|
Yield
|
-
|
-
|
Capitalization / Revenue
|
79.8
x
|
403
x
|
EV / Revenue
|
64
x
|
312
x
|
EV / EBITDA
|
-12.2
x
|
-5.4
x
|
EV / FCF
|
-
|
-6,965,831
x
|
FCF Yield
|
-
|
-0%
|
Price to Book
|
5.45
x
|
4.57
x
|
Nbr of stocks (in thousands)
|
22,467
|
23,071
|
Reference price
2 |
7,100
|
3,760
|
Announcement Date
|
3/21/24
|
3/21/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net sales
1 |
2,000
|
215.3
|
EBITDA
1 |
-10,491
|
-12,441
|
EBIT
1 |
-11,030
|
-13,228
|
Operating Margin
|
-551.5%
|
-6,145.52%
|
Earnings before Tax (EBT)
1 |
-10,683
|
-12,388
|
Net income
1 |
-10,673
|
-12,403
|
Net margin
|
-533.64%
|
-5,762.3%
|
EPS
2 |
-532.0
|
-540.6
|
Free Cash Flow
|
-
|
-9,648
|
FCF margin
|
-
|
-4,482.22%
|
FCF Conversion (EBITDA)
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
Dividend per Share
|
-
|
-
|
Announcement Date
|
3/21/24
|
3/21/24
|
Fiscal Period: December |
2022
|
2023
|
---|
Net Debt
1 |
-
|
-
|
Net Cash position
1 |
31,580
|
19,540
|
Leverage (Debt/EBITDA)
|
-
|
-
|
Free Cash Flow
|
-
|
-9,648
|
ROE (net income / shareholders' equity)
|
-
|
-51.4%
|
ROA (Net income/ Total Assets)
|
-
|
-27.5%
|
Assets
1 |
-
|
45,127
|
Book Value Per Share
2 |
1,303
|
823.0
|
Cash Flow per Share
2 |
193.0
|
280.0
|
Capex
1 |
187
|
1,907
|
Capex / Sales
|
9.36%
|
885.95%
|
Announcement Date
|
3/21/24
|
3/21/24
|
|
1st Jan change
|
Capi.
|
---|
| -50.93% | 30.64M | | +14.88% | 122B | | +19.55% | 113B | | +6.67% | 22.84B | | -18.69% | 20.72B | | -15.99% | 16.51B | | -14.34% | 16.39B | | -43.53% | 15.83B | | +2.17% | 13.49B | | +67.06% | 11.67B |
Bio Therapeutic Drugs
|